Teva Pharma B.V.

ACTIVE

Swensweg 5, Haarlem, Noord-Holland, Netherlandswww.tevapharm.comSubsidiary

Also known as:

teva b.v.

teva pharma

Part of Teva Pharmaceutical Industries Ltd.

Clinical Trials

0 active

Approvals

421

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

38.9%

Phase 2

22.2%

Phase 4

5.6%

Trial Status Distribution

Completed

83.3%

Recruiting

5.6%

Withdrawn

11.1%

Clinical Trials

Trials sponsored by this organization (18)

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

Completed

observational

Feb 201260 participants

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Chronic Cluster Headache

A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and pharmacodynamic profiles of TL011 infusions compared with MabThera® (rituximab) in subjects with severe, active rheumatoid arthritis treated with methotrexate (MTX)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the Prevention of Episodic Cluster Headache

A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma.

A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men.

Completed

interventional

93 participants

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

Page 1 of 3

Approvals

Approvals by Agency

EMA

European Medicines Agency

Approvals

EMC

Electronic Medicines Compendium

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

352

Approvals

Recent Approvals

IBUPROFENO/CAFEINA TEVA 400 MG/100 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

CIMA_AEMPS

2026-09-18

IVACAFTOR TEVA 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2026-09-01

LINAGLIPTINA TEVA 5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2026-07-23

GLICLAZIDA TEVAGEN 60 MG COMPRIMIDOS DE LIBERACIÓN MODIFICADA EFG

CIMA_AEMPS

2026-05-05

GLICLAZIDA TEVAGEN 30 MG COMPRIMIDOS DE LIBERACIÓN MODIFICADA EFG

CIMA_AEMPS

2026-05-05

AMLODIPINO TEVA-RATIOPHARM 5 MG COMPRIMIDOS EFG

CIMA_AEMPS

2025-12-22

APREMILAST TEVA 10 MG + 20 MG + 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2025-09-18

APREMILAST TEVA 30 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2025-09-18

TERIFLUNOMIDA TEVAGEN 14 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

CIMA_AEMPS

2025-09-18

PAXTIBI 25 MG COMPRIMIDOS RECUBIERTOS

CIMA_AEMPS

2025-07-14

News

No news articles found

Back to Organizations

Teva Pharma B.V.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (18)

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,<br>Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens<br>(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the<br>Prevention of Chronic Cluster Headache

A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and pharmacodynamic profiles of TL011 infusions compared with MabThera® (rituximab) in subjects with severe, active rheumatoid arthritis treated with methotrexate (MTX)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,<br>Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens<br>(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the<br>Prevention of Episodic Cluster Headache

A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma.

A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men.

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

Approvals

Approvals by Agency

Recent Approvals

News